Inventor · disambiguated record
Nora Pencheva
Also filed as: PENCHEVA NORA
8 granted patents·5 pending applications·97 citations·filing 2014–2024
88Inventor score
Top patents by PatentIndex Score
13 records- 0196US9707195B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2016·Granted Jul 18, 2017·22 cites·28 claims
- 0295US9962348B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2017·Granted May 8, 2018·15 cites·28 claims
- 0394US11865094B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2021·Granted Jan 9, 2024·2 cites·22 claims
- 0494US10945978B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2019·Granted Mar 16, 2021·3 cites·9 claims
- 0594US9526710B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2014·Granted Dec 27, 2016·20 cites·14 claims
- 0692US10543183B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2018·Granted Jan 28, 2020·7 cites·53 claims
- 0792US9399028B2Treatment of drug resistant cancerROCKEFELLER UNIV (THE)·Filed 2014·Granted Jul 26, 2016·28 cites·15 claims
- 0890US12502368B2Treatment and diagnosis of melanomaUNIV ROCKEFELLER·Filed 2024·Granted Dec 23, 2025·0 cites·21 claims
- 0958US2024409653A1Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancersGENMAB AS·Filed 2022·Application pending·0 cites
- 1058US2024262924A1Combination dosage regime of cd137 and pd-l1 binding agentsGENMAB AS·Filed 2022·Application pending·0 cites
- 1155US2025002600A1Multispecific binding agents against pd-l1 and cd137 in combination therapyGENMAB AS·Filed 2022·Application pending·0 cites
- 1247US2021070869A1Axl-specific antibodies for cancer treatmentGENMAB AS·Filed 2019·Application pending·0 cites
- 1347US2022273809A1Axl antibody-drug conjugates for use in treating cancerGENMAB AS·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nora Pencheva files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →